Islatravir + Etonogestrel/Ethinyl Estradiol 3D Printed IVR
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Pre-Clinical
- Developer(s)/researcher(s): University of North Carolina
Details
- API: Etonogestrel, Ethinyl Estradiol, Islatravir (EFdA)
- Target: Estrogen Receptor, Progesterone Receptor
-
Mechanism of Action:
- Endometrial Changes
- Cervical Mucus Changes
- Ovulation Inhibition
- Anti-Microbial
- Inactive Materials: Silicone-Urethane-Based Resin
- Regimen: 1 Ring/90 Days
- MPT: Potential MPT
- Promising Attributes: The method offers both pregnancy prevention and HIV prevention. The novel 3D printing process could lead to more rapid, scalable, and cost-effective manufacturing & improved API release.
Product Status
Active Pre-Clinical Research
History
2020: A novel approach to intravaginal ring design and manufacturing is published by the Benhabbour Research Laboratory.
2024: Results of in vitro release studies comparing the release of ENG and EE from 3D printed IVRs published. This study included the generation of a 90-day CLIP IVR that will be utilized in future work to support the development of a long-acting ENG/EE IVR combined with an antiretroviral for the prevention of HIV and unplanned pregnancy.